[1]Kaul AM, Goparaju S, Dvorina N, et al. Acute and chronic rejection: compartmentalization and kinetics of counterbalancing signals in cardiac transplants[J]. Am J Transplant, 2015,15(2):333-345.[2]Toki D, Zhang W, Hor KL, et al. The role of macrophages in the development of human renal allograft fibrosis in the first year after transplantation[J]. Am J Transplant, 2014,14(9):2126-2136.[3]Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets[J]. Nat Rev Immunol, 2011,11(11):723-737.[4]Rőszer T. Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms[J]. Mediators Inflamm, 2015,2015:816460.[5]Kong X, Gao J. Macrophage polarization: a key event in the secondary phase of acute spinal cord injury[J]. J Cell Mol Med, 2017,21(5):941-954.[6]Byrne AJ, Mathie SA, Gregory LG, et al. Pulmonary macrophages: key players in the innate defence of the airways[J]. Thorax, 2015,70(12):1189-1196.[7]Forbes SJ, Rosenthal N. Preparing the ground for tissue regeneration: from mechanism to therapy[J]. Nat Med, 2014,20(8):857-869.[8]Smith TD, Tse MJ, Read EL, et al. Regulation of macrophage polarization and plasticity by complex activation signals[J]. Integr Biol (Camb), 2016,8(9):946-955.[9]Chapman NM, Boothby MR, Chi H. Metabolic coordination of T cell quiescence and activation[J]. Nat Rev Immunol, 2020,20(1):55-70.[10]Schroder K, Sweet MJ, Hume DA. Signal integration between IFNgamma and TLR signalling pathways in macrophages[J]. Immunobiology, 2006,211(6-8):511-524.[11]Wu C, Zhao Y, Xiao X, et al. Graft-Infiltrating Macrophages Adopt an M2 Phenotype and Are Inhibited by Purinergic Receptor P2X7 Antagonist in Chronic Rejection[J]. Am J Transplant, 2016,16(9):2563-2573.[12]Kreimann K, Jang MS, Rong S, et al. Ischemia Reperfusion Injury Triggers CXCL13 Release and B-Cell Recruitment After Allogenic Kidney Transplantation[J]. Front Immunol, 2020,11:1204.[13]Zhang K, Sun YL, Zhou SN, et al. Circulating CXCR3-CCR6-CXCR5(+)CD4(+) T cells are associated with acute allograft rejection in liver transplantation[J]. Immunol Lett, 2019,213:55-61.[14]Aiello S, Podestà MA, Rodriguez-Ordonez PY, et al. Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c(+)F4/80(+) Macrophages through IL-1R8 Regulation[J]. J Am Soc Nephrol, 2020,31(3):517-531.[15]Gou W, Wang J, Song L, et al. Alpha-1 antitrypsin suppresses macrophage activation and promotes islet graft survival after intrahepatic islet transplantation[J]. Am J Transplant, 2021,21(5):1713-1724.[16]Gao C, Wang X, Lu J, et al. Mesenchymal stem cells transfected with sFgl2 inhibit the acute rejection of heart transplantation in mice by regulating macrophage activation[J]. Stem Cell Res Ther, 2020,11(1):241.[17]Liu X, Lu Y, Lian Y, et al. Macrophage Depletion Improves Chronic Rejection in Rats With Allograft Heart Transplantation[J]. Transplant Proc, 2020,52(3):992-1000.[18]Colvin-Adams M, Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future direction[J]. Clin Transplant, 2011,25(2):175-184.[19]Ferrer IR, Wagener ME, Song M, et al. CD154 blockade alters innate immune cell recruitment and programs alloreactive CD8+ T cells into KLRG-1(high) short-lived effector T cells[J]. PLoS One, 2012,7(7):e40559.[20]Krustrup D, Iversen M, Martinussen T, et al. Time elapsed after transplantation influences the relationship between the number of regulatory T cells in lung allograft biopsies and subsequent acute rejection episodes[J]. Transpl Immunol, 2014,31(1):42-47.[21]Chazaud B. Macrophages: supportive cells for tissue repair and regeneration[J]. Immunobiology, 2014,219(3):172-178.[22]Tse GH, Hughes J. Macrophages and transplant rejection: a novel future target?[J]. Transplantation, 2013,96(11):946-948.[23]Lodyga M, Hinz B. TGF-β1 - A truly transforming growth factor in fibrosis and immunity[J]. Semin Cell Dev Biol, 2020,101:123-139.[24]Wallace CH, Wu BX, Salem M, et al. B lymphocytes confer immune tolerance via cell surface GARP-TGF-β complex[J]. JCI Insight, 2018,3(7).[25]Liu M, Li S, Li MO. TGF-β Control of Adaptive Immune Tolerance: A Break From Treg Cells[J]. Bioessays, 2018,40(11):e1800063.[26]Chaudhry A, Samstein RM, Treuting P, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation[J]. Immunity, 2011,34(4):566-578.[27]Bacchetta R, Barzaghi F, Roncarolo MG. From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation[J]. Ann N Y Acad Sci, 2018,1417(1):5-22.[28]Bluestone JA, Tang Q. T(reg) cells-the next frontier of cell therapy[J]. Science, 2018,362(6411):154-155.[29]Demignot S, Beilstein F, Morel E. Triglyceride-rich lipoproteins and cytosolic lipid droplets in enterocytes: key players in intestinal physiology and metabolic disorders[J]. Biochimie, 2014,96:48-55.[30]Barnes MA, Carson MJ, Nair MG. Non-traditional cytokines: How catecholamines and adipokines influence macrophages in immunity, metabolism and the central nervous system[J]. Cytokine, 2015,72(2):210-219.[31]Zoccal KF, Paula-Silva FW, Bitencourt Cda S, et al. PPAR-γactivation by Tityus serrulatus venom regulates lipid body formation and lipid mediator production[J]. Toxicon, 2015,93:90-97.[32]Riquelme P, Tomiuk S, Kammler A, et al. IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients[J]. Mol Ther, 2013,21(2):409-422.[33]Spahn JH, Li W, Kreisel D. Innate immune cells in transplantation[J]. Curr Opin Organ Transplant, 2014,19(1):14-19.[34]Managh AJ, Hutchinson RW, Riquelme P, et al. Laser ablation-inductively coupled plasma mass spectrometry: an emerging technology for detecting rare cells in tissue sections[J]. J Immunol, 2014,193(5):2600-2608.
